124 related articles for article (PubMed ID: 28006994)
21. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
22. Preoperative markers for the prediction of high-risk features in endometrial cancer.
Panyavaranant P; Manchana T
World J Clin Oncol; 2020 Jun; 11(6):378-388. PubMed ID: 32874951
[TBL] [Abstract][Full Text] [Related]
23. Management of endometrial precancers.
Trimble CL; Method M; Leitao M; Lu K; Ioffe O; Hampton M; Higgins R; Zaino R; Mutter GL;
Obstet Gynecol; 2012 Nov; 120(5):1160-75. PubMed ID: 23090535
[TBL] [Abstract][Full Text] [Related]
24. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.
Deng L; Gao Y; Li X; Cai M; Wang H; Zhuang H; Tan M; Liu S; Hao Y; Lin B
J Exp Clin Cancer Res; 2015 Sep; 34(1):96. PubMed ID: 26362938
[TBL] [Abstract][Full Text] [Related]
25. Serum HE4 as a prognostic marker in endometrial cancer--a population based study.
Brennan DJ; Hackethal A; Metcalf AM; Coward J; Ferguson K; Oehler MK; Quinn MA; Janda M; Leung Y; Freemantle M; ; Webb PM; Spurdle AB; Obermair A
Gynecol Oncol; 2014 Jan; 132(1):159-65. PubMed ID: 24211402
[TBL] [Abstract][Full Text] [Related]
26. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.
Capriglione S; Plotti F; Miranda A; Ricciardi R; Scaletta G; Aloisi A; Guzzo F; Montera R; Angioli R
Tumour Biol; 2015 Jun; 36(6):4151-6. PubMed ID: 25577252
[TBL] [Abstract][Full Text] [Related]
27. Expression of HE4 in Endometrial Cancer and Its Clinical Significance.
Li X; Gao Y; Tan M; Zhuang H; Gao J; Hu Z; Wang H; Zhu L; Liu J; Lin B
Biomed Res Int; 2015; 2015():437468. PubMed ID: 26539494
[TBL] [Abstract][Full Text] [Related]
28. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.
Zanotti L; Bignotti E; Calza S; Bandiera E; Ruggeri G; Galli C; Tognon G; Ragnoli M; Romani C; Tassi RA; Caimi L; Odicino FE; Sartori E; Pecorelli S; Ravaggi A
Clin Chem Lab Med; 2012 Dec; 50(12):2189-98. PubMed ID: 23096757
[TBL] [Abstract][Full Text] [Related]
29. [Structural chromosome aberrations in the peripheral blood lymphocytes in patients with precancer and endometrial cancer].
Polishchuk LZ; Nesina IP
Tsitol Genet; 1995; 29(3):17-24. PubMed ID: 7676506
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer.
Kemik P; Saatli B; Yıldırım N; Kemik VD; Deveci B; Terek MC; Koçtürk S; Koyuncuoğlu M; Saygılı U
Gynecol Oncol; 2016 Jan; 140(1):64-9. PubMed ID: 26607777
[TBL] [Abstract][Full Text] [Related]
31. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia.
Janicek MF; Rosenshein NB
Gynecol Oncol; 1994 Mar; 52(3):373-8. PubMed ID: 8157194
[TBL] [Abstract][Full Text] [Related]
32. Detection of circulating tumour cells may add value in endometrial cancer management.
Ni T; Sun X; Shan B; Wang J; Liu Y; Gu SL; Wang YD
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():1-4. PubMed ID: 27756035
[TBL] [Abstract][Full Text] [Related]
33. The role of HE4 in differentiating benign and malignant endometrial pathology.
Gąsiorowska E; Magnowska M; Iżycka N; Warchoł W; Nowak-Markwitz E
Ginekol Pol; 2016; 87(4):260-4. PubMed ID: 27321096
[TBL] [Abstract][Full Text] [Related]
34. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer.
Espiau Romera A; Cuesta Guardiola T; Benito Vielba M; De Bonrostro Torralba C; Coronado Martín PJ; Baquedano Mainar L
Int J Gynaecol Obstet; 2020 Jun; 149(3):265-268. PubMed ID: 32147821
[TBL] [Abstract][Full Text] [Related]
35. Ki-67 index as an ancillary tool in the differential diagnosis of proliferative endometrial lesions with secretory change.
Gurda GT; Baras AS; Kurman RJ
Int J Gynecol Pathol; 2014 Mar; 33(2):114-9. PubMed ID: 24487464
[TBL] [Abstract][Full Text] [Related]
36. Hysteroscopic view in atypical endometrial hyperplasias: A correlation with pathologic findings on hysterectomy specimens.
Garuti G; Mirra M; Luerti M
J Minim Invasive Gynecol; 2006; 13(4):325-30. PubMed ID: 16825075
[TBL] [Abstract][Full Text] [Related]
37. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.
Rakha E; Wong SC; Soomro I; Chaudry Z; Sharma A; Deen S; Chan S; Abu J; Nunns D; Williamson K; McGregor A; Hammond R; Brown L
Am J Surg Pathol; 2012 Nov; 36(11):1683-90. PubMed ID: 23073327
[TBL] [Abstract][Full Text] [Related]
39. HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
Ørbo A; Arnes M; Lyså LM; Borgfeldt C; Straume B
Br J Cancer; 2016 Sep; 115(6):725-30. PubMed ID: 27537387
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Role of Human Epididymis Protein4 (HE4) in Endometrial Lesions: Study in a Tertiary Care Centre.
Das S; Saha R; Das C; Deb M; Kamilya G
Indian J Surg Oncol; 2023 Jun; 14(2):428-433. PubMed ID: 37324288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
